Aesthetic plastic surgery · 2025
Nerve Block-Assisted Intradermal Injection of Tranexamic Acid, Vitamin C, and Glutathione for Melasma: A Split-Face Comparative Study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Hongru, Yao Yu, Zhou Yuejie, Hu Jintian, Jang Liya
Аннотация
BACKGROUND: Melasma is a common acquired pigmentary disorder characterized by symmetrical hyperpigmented macules. However, combination therapy using tranexamic acid (TXA), vitamin C, and glutathione under nerve block remains inadequate.
OBJECTIVE: To evaluate the efficacy and safety of intradermal injection of TXA, vitamin C, and glutathione under nerve block for melasma treatment.
METHODS: A prospective, split-face trial was conducted on 20 patients with melasma during November 2023-July 2024. Lidocaine cream was applied to one side of the face, while infraorbital and zygomaticofacial nerve blocks were applied to the other. Intradermal injections of TXA, vitamin C, and glutathione were administered at weeks 2, 4, 6, and 8. Efficacy was assessed before treatment and three months post-treatment.
RESULTS: VISIA analysis showed significant increases in UV spots and brown spots (P < 0.001), indicating improved skin condition. Modified Melasma Area and Severity Index (mMASI) scores decreased significantly from 6.99 ± 1.62 to 4.50 ± 1.27 (P < 0.001). Visual analog scale (VAS) pain scores were higher on to topical anesthesia side (4.35 ± 1.22) compared to the nerve block side (2.50 ± 0.83) (P < 0.001). No severe adverse events were reported.
CONCLUSION: Intradermal injection of TXA, vitamin C, and glutathione under nerve block is an effective, safe, and low-pain treatment for melasma.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors https://www.springer.com/00266 .
OBJECTIVE: To evaluate the efficacy and safety of intradermal injection of TXA, vitamin C, and glutathione under nerve block for melasma treatment.
METHODS: A prospective, split-face trial was conducted on 20 patients with melasma during November 2023-July 2024. Lidocaine cream was applied to one side of the face, while infraorbital and zygomaticofacial nerve blocks were applied to the other. Intradermal injections of TXA, vitamin C, and glutathione were administered at weeks 2, 4, 6, and 8. Efficacy was assessed before treatment and three months post-treatment.
RESULTS: VISIA analysis showed significant increases in UV spots and brown spots (P < 0.001), indicating improved skin condition. Modified Melasma Area and Severity Index (mMASI) scores decreased significantly from 6.99 ± 1.62 to 4.50 ± 1.27 (P < 0.001). Visual analog scale (VAS) pain scores were higher on to topical anesthesia side (4.35 ± 1.22) compared to the nerve block side (2.50 ± 0.83) (P < 0.001). No severe adverse events were reported.
CONCLUSION: Intradermal injection of TXA, vitamin C, and glutathione under nerve block is an effective, safe, and low-pain treatment for melasma.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors https://www.springer.com/00266 .